Prevalence of genital human papillomavirus infections established using different diagnostic techniques among males attending a urological clinic

Carvalho, Júlio José Máximo; Syrjänen, Karí; Jacobino, M; Rosa, Naraja Teixeira; Carvalho, L Z M

doi:10.1080/00365590500191241

Cited by 14 publications

(9 citation statements)

References 20 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sequences used were (5¢ to 3¢) GCM CAG GGW CAT AAY GG (MY11, upstream primer position HPV6 ⁄ 6722-6741) and CGT CCM ARR GGA WAC TGA TC (MY09, downstream primer, position HPV 6 ⁄ 7170-7151) (14) (accession number for nucleotide sequence: U45939; Invitrogen Brazil Ltd.). These primers are designed to amplify DNA from genital HPV types 6,11,16,18,31,33,35,39,45,51, and 52 and were initially described for the detection of genital HPV as an appropriate diagnostic protocol for woman (14)(15)(16) and man (17) genital HPV infections. However, they have also been widely used to analyze skin lesions and oral mucosa (16,18,19).…”

Section: Laboratory Methodsmentioning

confidence: 99%

Oral and Genital Human Herpesvirus 8 and Human Papillomavirus in heterosexual partners

Brasil

Ribeiro

Leão

2012

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Section: Laboratory Methodsmentioning

confidence: 99%

Oral and Genital Human Herpesvirus 8 and Human Papillomavirus in heterosexual partners

Brasil

Ribeiro

Leão

2012

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…However, in calculating the HPV6/11 burden, we base our figures only on clinical lesions that can be detected by Pap smear in females [112,115] and by clinical examination or peniscopy in males [140,142,144,145]. In the case of males, this means the following clinical entities: exophytic genital warts (CA), flat condyloma, pigmented papulosis, Bowenoid papulosis and Bowen's disease [136,143Á145].…”

Section: Penismentioning

confidence: 99%

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland

Syrjänen¹

2009

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

In addition to cancer of the lower female genital tract, human papillomaviruses (HPV) are associated with a large number of benign, precancer and cancer lesions at different anatomic sites in both genders. Malignant tumours and their precursors are usually attributed to the oncogenic (high-risk, HR) HPV types, whereas benign lesions (papillomas) are associated with the low-risk (LR) HPV types, most notably with HPV6 and HPV11. Until recently, the main interest in HPV research has been focused on HR-HPV types and their associated pathology, and much less attention has been paid to the lesions caused by the LR-HPV types. With the recent licensing of an effective prophylactic vaccine against the 2 most important LR-HPV types (HPV6 and HPV11), it has become timely to make a systematic survey on the annual disease burden due to these 2 HPV genotypes in our country. These types of data should form the foundation for all calculations of the annual costs needed to treat these diseases by conventional means. Accurate estimates of disease burden are also mandatory for all modelling of the cost-effectiveness of prophylactic HPV6 and HPV11 vaccines. If proven useful for any of these purposes, this document will have fulfilled its purpose. In the first step, published HPV literature was used to create a list of benign, premalignant and malignant lesions associated with this virus at different anatomic sites. GLOBOCAN 2004 (IARC) database was used to derive the global numbers of incident cases for each of these malignancies in 2002, and the Finnish Cancer Registry (FCR) website for obtaining these (y 2005) numbers in Finland. The evidence linking HPV to each individual tumour category was classified as: 1) established, 2) emerging, and 3) controversial. All published evidence was weighted for each individual malignant, premalignant and benign lesion, anatomic region by region, while assessing the attributable fraction of HPV6/11 genotypes in each lesion. Because benign and most of the precancer lesions are not registered by FCR or GLOBOCAN, different approaches had to be used to derive the best estimates for their incidence, based on published literature or other registries (e.g. genital wart registry of the UK and Wales, and mass screening registry of FCR). With a lack of reasonable consensus, a lower and an upper limit was set for the range of estimates. In cases with different age-specific incidence (e.g. genital warts), the population pyramid of Finland was used to calculate the incident cases. Where well established, the different incidence rates among males and females were used to calculate the numbers of incident cases by gender. The malignant neoplasms with established or emerging evidence on the causal role of HPV are listed by their ICD-10 codes in Table I. Included in this list are also 2 controversial malignancies (colorectal cancer and endometrial cancer), of which the contradictory HPV data are critically discussed. The third major cancer in this same category (prostate cancer) was not included in the list, beca...

show abstract

“…15 Em relação à captura híbrida, o vírus foi identificado em 35,2% das lesões penianas sugestivas de infecção pelo HPV nas biópsias. 17 E quando os dois métodos foram associados observou-se 54% de sensibilidade nas lesões cervicais. 18 Todavia, usando o PCR, constatamos os HPV 6 e 11 nos casos de NIAA, o que nos permitiu concluir que tanto os tipos oncogênicos como os não oncogenicos podem estar associados com NIAA nos doentes HIV-positivos.…”

Section: 3unclassified

Papilomavirus humano e o câncer anal

Nadal

Manzione

2006

Rev bras. colo-proctol.

View full text Add to dashboard Cite

DOENÇAS SEXUALMENTE TRANSMISSÍVEIS ________________________O Papilomavirus humano (HPV) é uma das causas mais comuns de doença sexualmente transmissível, podendo provocar os condilomas acuminados que são considerados fatores de risco para displasia.1 Essa, que vem sendo chamada de neoplasia intraepitelial anal (NIA), é conseqüência da infecção crônica pelo HPV na região perianal e parece ser causada pela carga viral elevada. 2,3Embora a história natural dessa lesão seja incerta, 4,5 acredita-se que a NIA seja precursora do carcinoma anal. 16 Entretanto, a NIAA (de alto grau) parece ter baixo potencial para transformação maligna em doentes imunocompetentes e se espera que tenha incidência aumentada em imunodeprimidos, bem como determine mais alteração neoplásica. 5Sua incidência permanece elevada entre os homens HIV-positivos que praticam sexo com homens, mesmo após a introdução dos esquemas com drogas anti-retrovirais (ARV).2,3 Apesar da melhora da imunidade conferida por esse tratamento, o número de NIAA mantém-se similar ao período em que os inibidores da protease não eram disponíveis, 7 indicando a necessidade de prevenção do câncer anal nesses doentes, estejam ou não usando essa medicação. 2,3Nos homens que fazem sexo com homens (HSH) e com múltiplos parceiros sexuais, a prevalência RESUMO: O Papilomavirus humano (HPV) é uma das causas mais comuns de doença sexualmente transmissível, podendo provocar os condilomas acuminados que são considerados fatores de risco para displasia e neoplasia. Embora os HPV de alto risco sejam causa necessária para o câncer cervical, eventos genéticos adicionais são indispensáveis para transformação maligna da maioria dos carcinomas anais e de outros sítios. Os trabalhos da literatura especializada ainda não conseguiram demonstrar se esse vírus é o fato determinante ou associado ao carcinoma anal. É preciso que mais pesquisas sejam feitas para resolver esse dilema. De qualquer forma, sugerimos que o controle das lesões clínicas e das sub-clínicas provocadas pelo HPV possa evitar a eventual progressão para carcinoma invasivo.Descritores: Infecções por Papilllomavirus. Neoplasia intra-epitelial; prevenção e controle. Canal anal; citologia. Carcinoma de células escamosas.

show abstract

Prevalence of genital human papillomavirus infections established using different diagnostic techniques among males attending a urological clinic

Cited by 14 publications

References 20 publications

Oral and Genital Human Herpesvirus 8 and Human Papillomavirus in heterosexual partners

Oral and Genital Human Herpesvirus 8 and Human Papillomavirus in heterosexual partners

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland

Papilomavirus humano e o câncer anal

Contact Info

Product

Resources

About